NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

PANCREAS DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

Venue: Rossetti Room, Delta Chelsea Hotel, Toronto
Date: Saturday, April 28th, 2012
Time: 08:00 to 08:45 hrs
Chairs: Dr. Malcolm Moore & Dr. Steve Gallinger

08:00 WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE    Dr. D. Jonker

08:00 – 08:40 TRIALS/CONCEPTS IN DEVELOPMENT/PROCESS

A Randomized Crossover Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma: Results and Discussion of Next Steps

Drs T. Pearce and I. Melezínek

PA.6 (ACCORD 24): Randomized multicenter phase III comparison of adjuvant chemotherapy with gemcitabine versus a combination of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) in patients with resected pancreatic adenocarcinoma

Drs J. Biagi & A. Wei

08:40 – 08:45 INTERGROUP TASK FORCE UPDATE

08:45 CLOSING REMARKS